Overview of Financial Results for FY2021

CMIC HOLDINGS Co., Ltd.

November 5, 2021

Copyright ©2020 CMIC Group - All Rights Reserved

Business segments and group companies

- Blue indicates overseas group companies.

Segment

Products and services

CMIC Group companies (as of end of Sep. 2021)

CRO

Services related to pharmaceutical development support and analytical chemistry

CMIC HOLDINGS Co., Ltd.

Business

services

CMIC Co., Ltd.

CMIC ShiftZero K.K.

CMIC Korea Co., Ltd.

CMIC ASIA-PACIFIC, PTE. LTD.

CMIC ASIA PACIFIC (MALAYSIA) SDN. BHD.

CMIC Asia-Pacific (Hong Kong) Limited

CMIC ASIA-PACIFIC (PHILIPPINES), INC.

CMIC ASIA-PACIFIC (AUSTRALIA)PTY LTD

CMIC ASIA-PACIFIC (THAI LAND) LIMITED

CMIC ASIA-PACIFIC (VIETNAM) LIMITED

CMIC (Beijing) Co., Ltd.

CMIC DATA SCIENCE VIETNAM COMPANY LIMITED

CMIC Pharma Science Co., Ltd.

CMIC, INC.

CMIC CMO Co., Ltd.

CDMO

Services related to drug formulation development and manufacturing support, from

CMIC CMO NISHINE Co., Ltd.

Business

formulation design to investigational new drug manufacturing to commercial production

CMIC CMO Korea Co., Ltd.

of ethical drugs and nonprescription drugs for pharmaceutical companies

CMIC CMO USA Corporation

CMIC Bio Co., Ltd.

CSO

Services provided to pharma companies related to sales & marketing support

CMIC Ashfield Co., Ltd.

Business

Healthcare

SMO (Site Management Organization) and healthcare services related to treating and

CMIC HOLDINGS Co., Ltd.

maintaining and promoting the health for medical institutions, patients, and general

CMIC HealthCare Institute Co., Ltd.

Business

consumers, as well as services related to BPO (Business Process Outsourcing) and

CMIC Solutions Co., Ltd.

CMIC Well Co., Ltd.

human resources

IPM

Provision of new business solutions to pharmaceutical companies, etc. that combine

CMIC HOLDINGS Co., Ltd.

CMIC CMO Co., Ltd.

Business

value chains and marketing authorization licenses (intellectual properties) possessed by

our Group

OrphanPacific, Inc.

2

Main initiatives in the current term

  • Focus activities in the "Mid-term Plan (FY2019-2021)"
    • In addition to the PVC model, accelerate the IPM solution business that combines marketing authorization licenses
    • Strengthen area competitiveness and promote globalization
    • Create healthcare business
  • "Healthcare Revolution 2.0" (since July 2020)
    • Transform ourselves from business model centering on pharmaceutical drugs to creation of new healthcare business
    • Create new businesses that will contribute to maintaining and improving personal health
    • Utilize our talents in the healthcare arena

CONFIDENTIAL

3

Achievements in the fiscal year ended in September 2021

  • Contributing to COVID-19 countermeasures
  • Full fledged support for COVID-19 vaccination by local governments (mass vaccination, mobile vaccination) and preparation for workplace vaccination program
  • Utilization of the COVID-19 vaccination information management system "harmo® vaccine care with corona"
    • Total people registered on harmo vaccine app: 23,000

harmo vaccine care with Corona: 1.5 million shots, prescription record users: 420,000

  • Call center (to consult about adverse reactions), human resources supportPhysician and nurse reference, admin staff)
  • Commissioned by local governments, including Setagaya Ward (as social testing), to provide PCR testing services targeting nursing care providers, etc.
  • Support for clinical trials/post-marketing studies/clinical research, contract manufacturing of COVID-19 treatment drugs
  • Dedicated transportation service started for COVID-19 study subjects for smooth conduction of clinical trials amid COVID-19 outbreak

CONFIDENTIAL *harmo®: Healthcare Communication Channel 4

Achievements in the fiscal year ended in September 2021

  • Creating business that contributes to maintaining personal health
  • A harmo® project was designated by the Tokyo Metropolitan government as "Business to Establish the Next Generation Wellness Solution (a Project to Promote Commercialization)."
  • Have joined the Healthcare Open Innovation program hosted by Kouhoukai Group of International University of Health and Welfare, with the aim of developing pre-symptomatic disease prevention services and creating personalized healthcare services utilizing data.
  • Will launch "MONET LABO-HEALTHCARE," a medical MaaS (Mobility as a Service) specialized business development program, with MONET Technologies.Inc
  • Joint development agreement was concluded with ENEOS regarding the heat stress measurement system "lobesense"
  • Activities to support Digital Transformation in Healthcare "PSP (Patient Support Program) digital platform"

*MONET: Jointly established by SoftBank Corp., TOYOTA MOTOR CORPORATION, etc.

CONFIDENTIAL

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

CMIC Holdings Co. Ltd. published this content on 05 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 November 2021 07:32:23 UTC.